Tandem Diabetes Care (TNDM) Free Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 22.80% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -27.72% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -0.27% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 77.20% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -20.37% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.32% |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn | 30.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.33% |
| Dec 31, 2025 | -269.23% |
| Sep 30, 2025 | -5.97% |
| Jun 30, 2025 | -13.39% |
| Mar 31, 2025 | -57.46% |
| Dec 31, 2024 | 60.31% |
| Sep 30, 2024 | -13.82% |
| Jun 30, 2024 | -33.88% |
| Mar 31, 2024 | -34.78% |
| Dec 31, 2023 | -10.15% |
| Sep 30, 2023 | -33.59% |
| Jun 30, 2023 | -42.06% |
| Mar 31, 2023 | 6.50% |
| Dec 31, 2022 | -56.75% |
| Sep 30, 2022 | -21.02% |
| Jun 30, 2022 | -45.83% |
| Mar 31, 2022 | 58.96% |
| Dec 31, 2021 | -17.03% |
| Sep 30, 2021 | 127.88% |
| Jun 30, 2021 | 86.15% |
| Mar 31, 2021 | 61.63% |
| Dec 31, 2020 | 42.81% |
| Sep 30, 2020 | 43.03% |
| Jun 30, 2020 | 46.61% |
| Mar 31, 2020 | -9.20% |
| Dec 31, 2019 | 28.99% |
| Sep 30, 2019 | 44.60% |
| Jun 30, 2019 | 31.56% |
| Mar 31, 2019 | 30.37% |
| Dec 31, 2018 | 43.26% |
| Sep 30, 2018 | 41.30% |
| Jun 30, 2018 | 30.52% |
| Mar 31, 2018 | 7.97% |
| Dec 31, 2017 | -6.57% |
| Sep 30, 2017 | -1.10% |
| Jun 30, 2017 | -0.22% |
| Mar 31, 2017 | -4.23% |
| Dec 31, 2016 | -4.50% |
| Sep 30, 2016 | -18.91% |
| Jun 30, 2016 | -2.93% |
| Mar 31, 2016 | -19.05% |